Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Amortization of Deferred Charges (2020 - 2021)

Foghorn Therapeutics has reported Amortization of Deferred Charges over the past 2 years, most recently at $58000.0 for Q4 2021.

  • Quarterly results put Amortization of Deferred Charges at $58000.0 for Q4 2021, down 1.69% from a year ago — trailing twelve months through Sep 2022 was $58000.0 (down 81.82% YoY), and the annual figure for FY2021 was $318000.0, up 33.61%.
  • Amortization of Deferred Charges for Q4 2021 was $58000.0 at Foghorn Therapeutics, down from $88000.0 in the prior quarter.
  • Over the last five years, Amortization of Deferred Charges for FHTX hit a ceiling of $88000.0 in Q3 2021 and a floor of $53000.0 in Q3 2020.